Adoption of Pharmaceutical Trademarks for Approval: Navigating Differing Standards at the FDA and USPTO
Recording of a 90-minute premium CLE video webinar with Q&A
This CLE course will guide IP counsel on the complexities of the pharmaceutical trademark adoption process to support a successful launch of a company's new pharmaceutical product. In particular, the panel will discuss the challenges inherent in pharmaceutical brand development and approval, an overview of the pharmaceutical trademark adoption process from brainstorming to clearance, as well as the FDA trademark review process, and best practices to minimize the risk of rejection.
- Challenges to pharmaceutical trademark development and approval
- Differing approaches to trademark review by the USPTO and the FDA
- Overview of the pharmaceutical trademark adoption process
- Overview of the FDA trademark review process
- Best practices for adopting and clearing pharmaceutical trademarks and reducing the risk of rejection
The panel will review these and other priority issues:
- What unique challenges do pharmaceutical companies face in seeking to adopt trademarks for pharmaceuticals and biologics?
- What are the differences between the FDA trademark review process and the USPTO trademark review process, why, and what are the consequences?
- What best practices should companies employ for adopting and clearing pharmaceutical trademarks?
Ilene B. Tannen
Ms. Tannen specializes in trademark and copyright law and practices in the firm’s global Trademarks, Unfair... | Read More
Ms. Tannen specializes in trademark and copyright law and practices in the firm’s global Trademarks, Unfair Competition & Copyrights Group. She is also a former member of the Trademark Public Advisory Committee (TPAC) of the United States Patent and Trademark Office. Ms. Tannen manages global trademark portfolios for domestic and multinational companies, advising on clearance, brand development and use, registration strategies, and enforcement, in such industries as pharmaceuticals, telecommunications, apparel, sports, food and beverages, and financial services. She also counsels companies regarding the use of their intellectual property in online content and social media and advises clients regarding copyright protection and use. Ilene is the author of the U.S. Chapter in Thomson Reuters’ well-regarded, go-to trademark resource Trademarks Throughout the World, Fifth Edition, wherein she addresses trademark registration practice and procedures under U.S. trademark law.Close
Mr. Piergrossi serves as executive creative director for the company’s global brand naming projects and is... | Read More
Mr. Piergrossi serves as executive creative director for the company’s global brand naming projects and is responsible for the creative strategy and methodology used in name development. He has led thousands of brand naming projects during his 18 years with Brand Institute, primarily for pharmaceutical products and medical devices, clinical trials, line extensions/modifiers, companies, and consumer products. He is proficient in the disciplines related to the creation and marketing of brands, including strategy, positioning, trademark law, and regulatory affairs. As President, Operations & Communications, he led Brand Institute’s Miami-based operations and global corporate communications in his previous role as President. He continues to be head of corporate communications and media relations. He has appeared on/been quoted in various national/international print, radio, online, and television media, including CNN, CNBC, Bloomberg, CBS News Sunday Morning, NPR, STAT, Reuters, and the Miami Herald, among others.Close
Head, Legal Brand Protection, Global Oncology
Ms. Rao is Head of Legal Brand Protection at Novartis’ Global Oncology business. The Oncology business comprises... | Read More
Ms. Rao is Head of Legal Brand Protection at Novartis’ Global Oncology business. The Oncology business comprises hematology and solid tumors in four distinct therapeutic platforms: targeted therapy, cell and gene therapy, immunotherapy and radio-ligand therapy. She manages a team of IP professionals and works with an extended team of trademark and copyright attorneys and paralegals based in the United States and Switzerland. She sits on various leadership teams and she and her team counsel a wide range of internal client groups, including executives in all geographies and functions, such as, R&D, clinical, medical, and scientific affairs and communication, regulatory, and digital strategy and marketing. She has over 15 years of in-house experience at multinational pharmaceutical companies. Prior to Novartis, she was Trademark Counsel at Pfizer and Wyeth, supporting the consumer health, animal health, nutritional and pharmaceutical divisions. Before going in-house, she was an Associate and Of Counsel in private practice, where she litigated trademark and copyright cases, handled trademark prosecution, transactions and managed client portfolios in a variety of industries.Close